Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre V Hirayama

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Blood Advances|September 29, 2023
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLLEmily C Liang, Aya Albittar, Jennifer J Huang, et al.
Blood Advances|October 25, 2019
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapyMazyar Shadman, Jordan Gauthier, Kevin A Hay, et al.
Hematology, Transfusion and Cell Therapy|November 19, 2021
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphomaAlvaro J Alencar, Alexandre V Hirayama, Diego V Clé, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2023
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design StudyMichael Wang, Tanya Siddiqi, Leo I Gordon, et al.
Blood|February 21, 2020
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failureJordan Gauthier, Alexandre V Hirayama, Janaki Purushe, et al.
Plos One|June 6, 2024
qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissueShalini Pullarkat, Graeme Black, Marie Bleakley, et al.
JCI Insight|April 29, 2021
Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignanciesCarla S Walti, Elizabeth M Krantz, Joyce Maalouf, et al.
Blood Advances|January 17, 2025
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALLJordan Gauthier, Emily C Liang, Jennifer J Huang, et al.
Blood|April 19, 2022
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHLJordan Gauthier, Nicolas Gazeau, Alexandre V Hirayama, et al.
Haematologica|March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Blood Advances|September 29, 2023
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLLEmily C Liang, Aya Albittar, Jennifer J Huang, et al.
Blood Advances|October 25, 2019
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapyMazyar Shadman, Jordan Gauthier, Kevin A Hay, et al.
Hematology, Transfusion and Cell Therapy|November 19, 2021
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphomaAlvaro J Alencar, Alexandre V Hirayama, Diego V Clé, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2023
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design StudyMichael Wang, Tanya Siddiqi, Leo I Gordon, et al.
Blood|February 21, 2020
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failureJordan Gauthier, Alexandre V Hirayama, Janaki Purushe, et al.
Plos One|June 6, 2024
qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissueShalini Pullarkat, Graeme Black, Marie Bleakley, et al.
JCI Insight|April 29, 2021
Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignanciesCarla S Walti, Elizabeth M Krantz, Joyce Maalouf, et al.
Blood Advances|January 17, 2025
Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALLJordan Gauthier, Emily C Liang, Jennifer J Huang, et al.
Blood|April 19, 2022
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHLJordan Gauthier, Nicolas Gazeau, Alexandre V Hirayama, et al.
Haematologica|March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.
Pageof 4